SAB Biotherapeutics reports Q2 EPS ($1.09) vs. (79c) last year

Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We are extremely pleased to have recently raised $175 million in capital with oversubscribed participation which will enable us to fully fund the completion of our pivotal Phase 2b SAFEGUARD study for our lead candidate, SAB-142 for delaying the progression of type 1 diabetes. The proceeds will also extend our runway for another three years. This financing included not just the most well-known, top-tier investors in biotech but also the strategic investor Sanofi. Our recently completed financing is a testament to the strength of our science and the compelling and positive Phase 1 data shared in January. We look forward to advancing our novel disease-modifying multi-specific therapy, SAB-142, into a pivotal Phase 2b study in the third quarter of 2025 and moving us closer to potentially offering a disease-modifying therapy for patients with Stage 3 type 1 diabetes, the clinical diagnostic stage where patients start to exhibit symptoms.”